Final Efficacy and Safety Results of Pemetrexed Continuation Maintenance Therapy in the Elderly from the PARAMOUNT Phase III Study Cesare Gridelli, MD, Filippo de Marinis, MD, Michael Thomas, MD, Kumar Prabhash, MD, Claude El Kouri, MD, Fiona Blackhall, MD, Frederique Bustin, MD, Jean-Louis Pujol, MD, William J. John, MD, FACP, Belen San Antonio, PhD, Annamaria Zimmermann, MS, Nadia Chouaki, MD, Carla Visseren-Grul, MD, Luis G. Paz-Ares, MD, PhD Journal of Thoracic Oncology Volume 9, Issue 7, Pages 991-997 (July 2014) DOI: 10.1097/JTO.0000000000000207 Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 1 Kaplan-Meier curves of progression-free survival (PFS) and overall survival (OS). A, B. PFS for elderly (A) and non-elderly (B) patients measured from randomization. C, D. OS for the elderly (C) and non-elderly (D) measured from randomization. Median survival times in months and unadjusted hazard ratios are shown on each graph, followed by 95% confidence intervals listed in parentheses. BSC, best supportive care; NE, not evaluable; CI, confidence interval; mo, months; HR, hazard ratio; Pem, pemetrexed; Plc, placebo. Journal of Thoracic Oncology 2014 9, 991-997DOI: (10.1097/JTO.0000000000000207) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 2 Cumulative grade 3/4 fatigue, anemia, and neutropenia during maintenance pemetrexed. Journal of Thoracic Oncology 2014 9, 991-997DOI: (10.1097/JTO.0000000000000207) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions